CGA
RPRX icon

Compound Global Advisors’s Royalty Pharma RPRX Stock Holding History

Compound Global Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-626,412
Closed -$17M – 40
2023
Q3 		$17M Buy
+626,412
New +$18.6M 3.73% 12

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Compound Global Advisors's RPRX Position: Q1 2024 in Review

Compound Global Advisors reduced its Royalty Pharma (RPRX) stake by 17% in Q1 2024, selling an estimated $2.44M and leaving 396,342 shares worth $12M. The position accounts for 1.79% of the portfolio, ranked #19.

Compound Global Advisors first reported a position in RPRX in Q2 2023 and has held it in 3 quarters since. The position peaked at $16.7M in Q2 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Compound Global Advisors held 396,342 shares of Royalty Pharma worth $12M as of Q1 2024.
  • Compound Global Advisors sold 82,906 Royalty Pharma shares in Q1 2024, an estimated $2.44M.
  • Royalty Pharma made up 1.79% of Compound Global Advisors's portfolio in Q1 2024, its #19 holding.
  • Compound Global Advisors first reported a position in Royalty Pharma in Q2 2023 and has held it in 3 quarters since.
  • Compound Global Advisors's Royalty Pharma position peaked at $16.7M in Q2 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Compound Global Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.